MedTrace Logo

RIXUBIS PMS India (RIXUBIS PMS)

NCT03565237 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-08-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to characterize the safety and describe the effectiveness of RIXUBIS in routine clinical practice.

Conditions

  • Hemophilia B

Interventions

BIOLOGICAL

RIXUBIS: On-Demand

RIXUBIS used under standard clinical practice in India: On-Demand treatment.

BIOLOGICAL

RIXUBIS: Prophylaxis

RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.

Sponsors & Collaborators

  • Baxalta Innovations GmbH, now part of Shire

    collaborator INDUSTRY

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-07
Primary Completion
2021-08-11
Completion
2021-08-11
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03565237 on ClinicalTrials.gov